Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients >75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.
At discharge from the hospital, patients that meet the inclusion criteria are offered to participate in the study. At this point the investigators will also gather baseline data through questionnaires on self-reported adherence (MARS-5) and quality of life (EQ-5D). The participants are randomized to the different study arms according to a stratified procedure based on their cognitive function.
The intervention group will have their charts reviewed every second week and be contacted by the clinical pharmacist through phone within 7 and after 30 and 60 days respectively to discuss their medications. If possible drug-related problems are suspected during the interviews that cannot be solved immediately, the physician is contacted.
Both groups have a follow-up time of 30 and 180 days. After 30 and 180 days, the patients will once again report adherence and quality of life. All other data can be gathered from the medical charts.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Intervention group | Experimental | In addition to a standard medication review at the hospital, this group also receives an enhanced clinical pharmacist service during 180 days after discharge from the hospital. |
|
| Control group | No Intervention | This group receives standard care, which might include a medication review at the hospital. |
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Enhanced clinical pharmacist service | Other | The intervention includes regular medical chart reviews, multiple patient interviews and, if needed, collaboration with the primary care physician. |
| Measure | Description | Time Frame |
|---|---|---|
| Time from discharge to first drug-related readmission | Survival analysis with drug-related readmission as endpoint | 180 days |
| Measure | Description | Time Frame |
|---|---|---|
| Time from discharge to first drug-related readmission | Survival analysis with drug-related readmission as endpoint | 30 days |
| Frequency of drug-related readmissions | Difference in total number of drug-related readmissions |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Kindstedt | Contact | +46706572422 | jonas.kindstedt@umu.se | |
| Maria Gustafsson, Ph.D | Contact | +46907853562 | maria.gustafsson@umu.se |
| Name | Affiliation | Role |
|---|---|---|
| Maria Gustafsson, Ph.D | Umeå University | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Medical Centre, University Hospital of Umeå | Recruiting | Umeå | 901 85 | Sweden |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 32345700 | Derived | Kindstedt J, Svahn S, Sjolander M, Glader EL, Lovheim H, Gustafsson M. Investigating the effect of clinical pharmacist intervention in transitions of care on drug-related hospital readmissions among the elderly: study protocol for a randomised controlled trial. BMJ Open. 2020 Apr 27;10(4):e036650. doi: 10.1136/bmjopen-2019-036650. |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
A group of physicians and clinical pharmacists will asses whether readmissions are drug-related or not. This group is blinded.
| 30 and 180 days |
| Time from discharge to first drug-related readmission - subgroups with/without heart failure | Survival analysis among patients with/without heart failure | 30 and 180 days |
| Time from discharge to first drug-related readmission - subgroups with/without cognitive impairment | Survival analysis among patients with/without cognitive impairment | 30 and 180 days |
| Frequency of drug-related readmissions - subgroups with/without cognitive impairment | Subgroup analysis among patients with/without cognitive impairment | 30 and 180 days |
| Frequency of drug-related readmissions - subgroups with/without heart failure | Subgroup analysis among patients with/without heart failure | 30 and 180 days |
| Time from discharge to first all-cause hospital visit | Survival analysis with readmission or visit to the emergency department as endpoint | 30 and 180 days |
| Frequency of all-cause hospital visits | Difference in total number of readmissions and visits to the emergency department | 30 and 180 days |
| Self-reported adherence | Adherence to medications reported through MARS-5 ( Medication Adherence Rating Scale) and Swedish Prescribed Drug Register | 30 and 180 days |
| Self assessed quality of life: EQ-5D-questionnaire | Health-related quality of life reported through the EQ-5D-questionnaire | 30 and 180 days |
| Health economics | Cost for visits for (drug-related) readmissions and to visits to the Emergency Department compared between patients in the control group and intervention group. | 180 days |
| Medication appropriateness | Medication appropriateness using the implicit Medication Appropriateness Index (MAI) and explicit tools in the form of the quality indicators published by the Swedish National Board of Health and Welfare and The European Union (EU)(7)-PIM list | 180 days |
| Mortality | Survival analysis with death as endpoint | 30 and 180 days |